Literature DB >> 34270347

Longitudinal Observation of Insulin Use and Glucose Sensor Metrics in Pregnant Women with Type 1 Diabetes Using Continuous Glucose Monitors and Insulin Pumps: The LOIS-P Study.

Grenye O'Malley1, Basak Ozaslan2, Carol J Levy1, Kristin Castorino3, Donna Desjardins4, Camilla Levister1, Shelly McCrady-Spitzer4, Mei Mei Church3, Ravinder Jeet Kaur4, Corey Reid4, Walter K Kremers4, Francis J Doyle2, Mari Charisse Trinidad5, Barak Rosenn6, Jordan E Pinsker3, Yogish C Kudva4, Eyal Dassau2.   

Abstract

Background: Suboptimal glycemic control is associated with maternal and neonatal morbidity and mortality in pregnancy complicated by type 1 diabetes (T1D). Prospective analysis of continuous glucose monitoring (CGM) metrics, insulin pump settings, and insulin delivery can better characterize the changes in glycemic levels and insulin use throughout pregnancy with T1D. Materials and
Methods: Prescribed parameters, insulin delivery, carbohydrate intake, and CGM data for 25 pregnant women with T1D from three U.S. sites were collected. Participants enrolled before 17 weeks gestation and used personal insulin pumps and study CGM. Mean daily total, basal, and bolus insulin doses (units/kg), CGM time in range (TIR: 63-140 mg/dL), and pump-entered carbohydrates were analyzed for every 2-week gestational interval. Linear mixed-effects regression models were used to evaluate changes across gestational ages compared to 12-14 weeks.
Results: Basal insulin was higher during weeks 6-12 and 24-40. Daily bolus and total insulin were higher during weeks 20-40. Pump parameters were adjusted to intensify insulin therapy from 22 weeks onward. Average TIR across pregnancy was 59% ± 14%. Between 18 and 30 weeks, TIR was significantly lower, and time above range was significantly higher compared to the reference biweek. Time below target was lower between 22 and 34 weeks. Seven participants achieved >70% recommended TIR for pregnancy. Participants with maternal complications or infant neonatal intensive care unit admissions had lower TIR.
Conclusion: While insulin dosing changed significantly with advancing gestation, most participants did not achieve >70% TIR. Customized anticipatory pump setting adjustments and automated systems aimed toward the designated TIR are needed to improve outcomes for this population. NCT03761615.

Entities:  

Keywords:  Continuous glucose monitoring; Insulin pump therapy; Pregnancy; Type 1 diabetes

Mesh:

Substances:

Year:  2021        PMID: 34270347      PMCID: PMC9057877          DOI: 10.1089/dia.2021.0112

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   7.337


  24 in total

Review 1.  Hypoglycaemia during pregnancy in women with Type 1 diabetes.

Authors:  L Ringholm; U Pedersen-Bjergaard; B Thorsteinsson; P Damm; E R Mathiesen
Journal:  Diabet Med       Date:  2012-05       Impact factor: 4.359

2.  Perinatal mortality and congenital anomalies in babies of women with type 1 or type 2 diabetes in England, Wales, and Northern Ireland: population based study.

Authors:  Mary C M Macintosh; Kate M Fleming; Jaron A Bailey; Pat Doyle; Jo Modder; Dominique Acolet; Shona Golightly; Alison Miller
Journal:  BMJ       Date:  2006-06-16

3.  Pumps or Multiple Daily Injections in Pregnancy Involving Type 1 Diabetes: A Prespecified Analysis of the CONCEPTT Randomized Trial.

Authors:  Denice S Feig; Rosa Corcoy; Lois E Donovan; Kellie E Murphy; Jon F R Barrett; J Johanna Sanchez; Tim Wysocki; Katrina Ruedy; Craig Kollman; George Tomlinson; Helen R Murphy
Journal:  Diabetes Care       Date:  2018-10-16       Impact factor: 19.112

4.  Outcomes in type 1 diabetic pregnancies: a nationwide, population-based study.

Authors:  Dorte M Jensen; Peter Damm; Lars Moelsted-Pedersen; Per Ovesen; Jes G Westergaard; Margrethe Moeller; Henning Beck-Nielsen
Journal:  Diabetes Care       Date:  2004-12       Impact factor: 19.112

5.  Macrosomia in well controlled CSII treated Type I diabetic pregnancy.

Authors:  Ohad Cohen; Naomi Keidar; Michal Simchen; Boaz Weisz; Mordechai Dolitsky; Eyal Sivan
Journal:  Gynecol Endocrinol       Date:  2008-11       Impact factor: 2.260

6.  Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands.

Authors:  Inge M Evers; Harold W de Valk; Gerard H A Visser
Journal:  BMJ       Date:  2004-04-05

7.  Diabetes Technology Use Among Pregnant and Nonpregnant Women with T1D in the T1D Exchange.

Authors:  Sarit Polsky; Mengdi Wu; Bruce W Bode; Stephanie N DuBose; Robin S Goland; David M Maahs; Nicole C Foster; Anne L Peters; Carol J Levy; Viral N Shah; Roy W Beck
Journal:  Diabetes Technol Ther       Date:  2018-07-10       Impact factor: 6.118

8.  Glycemic targets in the second and third trimester of pregnancy for women with type 1 diabetes.

Authors:  Michael J A Maresh; Valerie A Holmes; Christopher C Patterson; Ian S Young; Donald W M Pearson; James D Walker; David R McCance
Journal:  Diabetes Care       Date:  2014-11-03       Impact factor: 19.112

9.  Improved pregnancy outcomes in women with type 1 and type 2 diabetes but substantial clinic-to-clinic variations: a prospective nationwide study.

Authors:  Helen R Murphy; Ruth Bell; Cher Cartwright; Paula Curnow; Michael Maresh; Margery Morgan; Catherine Sylvester; Bob Young; Nick Lewis-Barned
Journal:  Diabetologia       Date:  2017-06-08       Impact factor: 10.122

10.  Continuous glucose monitoring in pregnant women with type 1 diabetes: an observational cohort study of 186 pregnancies.

Authors:  Karl Kristensen; Linda E Ögge; Verena Sengpiel; Karin Kjölhede; Annika Dotevall; Anders Elfvin; Filip K Knop; Nana Wiberg; Anastasia Katsarou; Nael Shaat; Lars Kristensen; Kerstin Berntorp
Journal:  Diabetologia       Date:  2019-03-23       Impact factor: 10.122

View more
  5 in total

Review 1.  Assessing Glycemic Control Using CGM for Women with Diabetes in Pregnancy.

Authors:  Grenye O'Malley; Ally Wang; Selassie Ogyaadu; Carol J Levy
Journal:  Curr Diab Rep       Date:  2021-11-04       Impact factor: 4.810

2.  Hypoglycemia in Prospective Multicenter Study of Pregnancies with Pre-Existing Type 1 Diabetes on Sensor-Augmented Pump Therapy: The LOIS-P Study.

Authors:  Ravinder Jeet Kaur; Byron H Smith; Basak Ozaslan; Jordan E Pinsker; Mari Charisse Trinidad; Grenye O'Malley; Donna Desjardins; Kristin N Castorino; Camilla Levister; Corey Reid; Shelly McCrady-Spitzer; Selassie J Ogyaadu; Mei Mei Church; Molly Piper; Walter K Kremers; Barak Rosenn; Francis J Doyle; Eyal Dassau; Carol J Levy; Yogish C Kudva
Journal:  Diabetes Technol Ther       Date:  2022-08       Impact factor: 7.337

3.  Feasibility of Closed-Loop Insulin Delivery with a Pregnancy-Specific Zone Model Predictive Control Algorithm.

Authors:  Basak Ozaslan; Carol J Levy; Yogish C Kudva; Jordan E Pinsker; Grenye O'Malley; Ravinder Jeet Kaur; Kristin Castorino; Camilla Levister; Mari Charisse Trinidad; Donna Desjardins; Mei Mei Church; Mitchell Plesser; Shelly McCrady-Spitzer; Selassie Ogyaadu; Kristen Nelson; Corey Reid; Sunil Deshpande; Walter K Kremers; Francis J Doyle; Barak Rosenn; Eyal Dassau
Journal:  Diabetes Technol Ther       Date:  2022-04-26       Impact factor: 7.337

4.  Zone-MPC Automated Insulin Delivery Algorithm Tuned for Pregnancy Complicated by Type 1 Diabetes.

Authors:  Basak Ozaslan; Sunil Deshpande; Francis J Doyle; Eyal Dassau
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-22       Impact factor: 5.555

5.  AiDAPT: automated insulin delivery amongst pregnant women with type 1 diabetes: a multicentre randomized controlled trial - study protocol.

Authors:  Tara T M Lee; Corinne Collett; Mei-See Man; Matt Hammond; Lee Shepstone; Sara Hartnell; Eleanor Gurnell; Caroline Byrne; Eleanor M Scott; Robert S Lindsay; Damian Morris; Anna Brackenridge; Anna R Dover; Rebecca M Reynolds; Katharine F Hunt; David R McCance; Katharine Barnard-Kelly; David Rankin; Julia Lawton; Laura E Bocchino; Judy Sibayan; Craig Kollman; Malgorzata E Wilinska; Roman Hovorka; Helen R Murphy
Journal:  BMC Pregnancy Childbirth       Date:  2022-04-05       Impact factor: 3.007

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.